Saturday, September 23, 2023
Saturday, September 23, 2023

Northwell Nurse Sandra Lindsay is 1st for Pfizer COVID Vaccine – Again

The first American to receive the COVID-19 vaccine in 2020 repeated the feat again today as part of a public health awareness event. Sandra Lindsay, RN, became a global phenomenon on December 14, 2020, when the Northwell Health critical care nurse director received the Pfizer-BioNTech COVID-19 vaccine.

Nearly three years later, Nurse Lindsay volunteered to be the first American to receive this season’s shot: Pfizer-BioNTech 2023-24 COVID-19 vaccine. This mRNA formulation offers protection against BA.2, BA.2.86 “Pirola,” EG.5 “Eris,” XBB.1.5 COVID variants – needed immunity as COVID hospitalizations begin to rise ahead of the fall and winter season.

Despite serving on the front lines of the pandemic, Nurse Lindsay has yet to be infected with COVID-19. “It’s important that people understand that COVID is still around and can still severely affect an individual,” said Nurse Lindsay. “Having worked through the darkest days of the pandemic and seen the devastating effects it can have, I tell people not to take chances. We have powerful weapons like vaccines to prevent those devastating outcomes.”

This was the third COVID-19 vaccine – and sixth, including boosters – taken by Nurse Lindsay, who has since been elevated to the role of vice president of public health advocacy at Northwell. The FDA approved Pfizer’s vaccine on Monday followed by the CDC’s Advisory Committee on Immunization Practices on Tuesday.

Michelle Chester, FNP-BC, DNP, senior director of Employee Health Services at Northwell, administered the shot. She also gave Nurse Lindsay the vaccine in 2020. Also joining Nurse Lindsay in receiving vaccinations were: Adam Berman, MD, associate chair of emergency medicine at Long Island Jewish Medical Center in New Hyde Park; Mozhdeh Mehrabian, a respiratory therapist at North Shore University Hospital in Manhasset; and Mangala Narasimhan, MD, senior vice president of critical care services at Northwell.

“Vaccination is and has proven to be an important tool to fight against the severity of COVID-19,” said Jill Kalman, MD, chief medical officer and deputy physician in chief at Northwell Health. “We’re here now to reinforce that there is extra protection available against the newest COVID-19 variants as the FDA and CDC have approved a new seasonal vaccine.”

Northwell has administered about 800,000 doses of COVID-19 vaccine since the end of 2020. The FDA and CDC have said the vaccine is safe and effective for anyone ages 6 months and older. Northwell Health will offer both Pfizer and Moderna vaccines to its employees and the general public through its ambulatory network once it receives doses.

“It’s been three-and-a-half years since COVID hit the world and we have not forgotten,” said Bruce Farber, MD, chief of public health and epidemiology at Northwell. “At the peak of the First Wave, our health system had nearly 3,500 hospitalized COVID patients. This week, it’s less than 200. Even though that number has bumped up considerable since July, the majority are incidental cases, meaning that they have been hospitalized for some other reason. Nevertheless, COVID causes at lot of morbidity and it interrupts lives. That’s why we support vaccines as a major way to prevent COVID.”

Dr. Farber also warned of a surge later this fall and into the winter – another possible “tripledemic” of COVID, flu and RSV – unless Americans embrace vaccines. Flu and COVID vaccines can be taken at the same time. RSV is also available and should be considered for at-risk populations.

Northwell Health is New York State’s largest health system and private employer.


Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

FDA OK’s ensoETM for Use in Cardiac Ablations to Reduce Risk of Esophageal Injury

Published studies that have examined the use of ensoETM for this purpose include the pilot eCOOL-AF study, the IMPACT study and a large multi-center analysis of over 25,000 patients (in press at the Journal of the American College of Cardiology: Clinical Electrophysiology). These studies have found up to an 83 percent reduction in esophageal injuries, and a significant reduction in risk of atrioesophageal fistula (AEF), one of the most dreaded complications of ablation procedures. Receives FDA Clearance and Breakthrough Device Designation has also received FDA Breakthrough Device Designation for its obstructive hydrocephalus software tool. This is the first radiology triage device to be granted Breakthrough status since the inception of the FDA Breakthrough Devices Program.

By using this website you agree to accept Medical Device News Magazine Privacy Policy